TickerFacts.

Tarsus Pharmaceuticals, Inc. (TARS): Long-Term Debt

Annual figures by period end, from SEC filings.

$72.44M
As of 2025-12-31
$72.76M
As of 2026-06-30
+55.0%
3-year compound annual growth
2022-12-31: $19.43M2023-12-31: $29.82M2024-12-31: $71.84M2025-12-31: $72.44M$72.44M
2022-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$72.44M+0.8%2026-02-23, Balance as of period end
2024-12-31$71.84M+140.9%2026-02-23, Balance as of period end
2023-12-31$29.82M+53.4%2025-02-25, Balance as of period end
2022-12-31$19.43Mn/a2024-02-27, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31$72.44M+0.8%
ADMA Biologics, Inc. (ADMA)2025-12-31$72.14M-0.3%
Repligen Corp (RGEN)2025-12-31$542.21M+3.2%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$54.28Mn/a
Halozyme Therapeutics, Inc. (HALO)2025-12-31$2.14B+42.3%
Agenus Inc (AGEN)2025-12-31$44.66M+34.6%
Qiagen N.V. (QGEN)2025-12-31$1.65B+18.9%
Fennec Pharmaceuticals Inc. (FENC)2024-12-31$19.34M-37.5%
Editas Medicine, Inc. (EDIT)2024-12-31$57.43Mn/a

Compare TARS, ADMA, RGEN, ADAPY side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗